Cutaneous manifestations in neurofibromatosis type 1

被引:36
|
作者
Miraglia, E. [1 ]
Moliterni, E. [1 ]
Lacovino, C. [1 ]
Roberti, V [1 ]
Laghi, A. [1 ]
Moramarco, A. [2 ]
Giustini, S. [1 ]
机构
[1] Sapienza Univ Rome, Dermatol Clin, Rome, Italy
[2] Sapienza Univ Rome, Dept Sense Organs, Rome, Italy
来源
CLINICA TERAPEUTICA | 2020年 / 171卷 / 05期
关键词
Cafe-au-lait macules; cutaneous manifestations; freckling; neurofibromatosis type 1; neurofibroma; neurofibromin; RETINAL MICROVASCULAR ABNORMALITIES; AU LAIT MACULES; POLIOSIS CIRCUMSCRIPTA; BECKERS NEVUS; IN-VIVO; NF1; PATIENT; ASSOCIATION; EXPERIENCE; SPOTS;
D O I
10.7417/CT.2020.2242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To better understand the real prevalence of cutaneous manifestations, in Neurofibromatosis type 1. Materials and Methods. We reviewed all clinical charts of 1102 NF1 patients followed by February 1983 to February 2020 at the "Sapienza" University of Rome, Italy. NF1 patients are seen usually every year by a dermatologist. Results. Cafe-au-lait macules were shown in 1063 patients (96.5%), axillary and inguinal freckling in 991 (90%) and neurofibromas in 861 (78.1%). Other skin manifestations included: lipoma (6.2%), nevus anemicus (3.9%), psoriasis (3.4%), spilus nevus (3.2%), juvenile xanthogranuloma ( 3.2%), vitiligo (2.3%), Becker's nevus (1.9%), melanoma (0.7%) and poliosis (0.5%). Conclusions. Neurofibromatosis type 1 is a multisystem disorder primarily involving the skin and nervous system. The clinical manifestations are extremely variable even within a family. This study was performed to delineate the prevalence of cutaneous manifestations in NF1.
引用
收藏
页码:E371 / E377
页数:7
相关论文
共 50 条
  • [31] Melanocytic neoplasms in neurofibromatosis type 1: a systematic review
    Meyer, Summer N.
    Simmons, Elanee
    Studer, Amy C.
    Rauen, Katherine A.
    Kiuru, Maija
    MELANOMA RESEARCH, 2023, 33 (06) : 437 - 446
  • [32] Cutaneous Manifestations of Type-II Diabetes Mellitus
    Baloch, Ghulam Hussain
    Memon, Noor Mohammad
    Devrajani, Bikha Ram
    Iqbal, Pervez
    Thebo, Nasreen Khalid
    JOURNAL OF THE LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, 2008, 7 (02): : 67 - 70
  • [33] Desmoplastic melanoma of the eyelid and conjunctival melanoma in neurofibromatosis type 1: A clinical pathological correlation
    Rubinstein, Tal J.
    Plesec, Thomas P.
    Singh, Arun D.
    SURVEY OF OPHTHALMOLOGY, 2015, 60 (01) : 72 - 77
  • [34] Endocrinological Evaluations of a Neurofibromatosis Type 1 Cohort: Is it Necessary to Evaluate Autoimmune Thyroiditis in Neurofibromatosis Type 1?
    Guler, Serhat
    Yesil, Gozde
    Onal, Hasan
    BALKAN MEDICAL JOURNAL, 2017, 34 (06) : 522 - 526
  • [35] A patient with neurofibromatosis type 1 and myotonic dystrophy type 1
    Esra, Serdaroglu
    Ceren, Gunbey
    Banu, Anlar
    NEUROLOGY ASIA, 2022, 27 (02) : 503 - 506
  • [36] Neurofibromatosis type 1 and infantile spasms
    Ruggieri, Martino
    Iannetti, Paola
    Clementi, Maurizio
    Polizzi, Agata
    Incorpora, Gemma
    Spalice, Alberto
    Pavone, Piero
    Pratico, Andrea Domenico
    Elia, Maurizio
    Gabriele, Anna Lia
    Tenconi, Romano
    Pavone, Lorenzo
    CHILDS NERVOUS SYSTEM, 2009, 25 (02) : 211 - 216
  • [37] Diagnosis and management of neurofibromatosis type 1
    Korf B.R.
    Current Neurology and Neuroscience Reports, 2001, 1 (2) : 162 - 167
  • [38] Learning disorders in neurofibromatosis type 1
    Jose Garcia-Penas, Juan
    REVISTA DE NEUROLOGIA, 2017, 64 : S59 - S63
  • [39] Perioperative Management of Neurofibromatosis Type 1
    Fox, Charles J.
    Tomajian, Samir
    Kaye, Aaron J.
    Russo, Stephanie
    Abadie, Jacqueline Volpi
    Kaye, Alan D.
    OCHSNER JOURNAL, 2012, 12 (02): : 111 - 121
  • [40] Statins, bone, and neurofibromatosis type 1
    Bruce R Korf
    BMC Medicine, 6